Whales with a lot of money to spend have taken a noticeably bearish stance on DexCom.

Looking at options history for DexCom (NASDAQ:DXCM) we detected 11 trades.

If we consider the specifics of each trade, it is accurate to state that 27% of the investors opened trades with bullish expectations and 72% with bearish.

From the overall spotted trades, 5 are puts, for a total amount of $244,311 and 6, calls, for a total amount of $241,450.

Projected Price Targets

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $105.0 and $130.0 for DexCom, spanning the last three months.

Volume & Open Interest Development

Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for DexCom's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DexCom's whale trades within a strike price range from $105.0 to $130.0 in the last 30 days.

DexCom 30-Day Option Volume & Interest Snapshot

Noteworthy Options Activity:

About DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Following our analysis of the options activities associated with DexCom, we pivot to a closer look at the company's own performance.

DexCom's Current Market Status

• Trading volume stands at 1,999,591, with DXCM's price down by -0.85%, positioned at $122.24.
• RSI indicators show the stock to be may be approaching overbought.
• Earnings announcement expected in 50 days.

Expert Opinions on DexCom

In the last month, 3 experts released ratings on this stock with an average target price of $136.0.

• Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for DexCom, targeting a price of $122.
• Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on DexCom with a target price of $150.
• An analyst from Wells Fargo persists with their Overweight rating on DexCom, maintaining a target price of $136.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DexCom with Benzinga Pro for real-time alerts.